The authors wish to make the following changes to their paper \[[@B1-diseases-06-00061]\]. In Table 1, in the last row, the authors reported rates of Neutralizing antibodies: 42% vs. 6% in ODYSSEY Outcomes. Actually, these are patient numbers and not percentages. Due to this fact, we would like to correct this data as 0.4% vs. 0.1% in Table 1. This correction has been made in both Table 1 and in the main text.

Former [Table 1](#diseases-06-00061-t001){ref-type="table"}:

New [Table 1](#diseases-06-00061-t002){ref-type="table"}

The mistake in the main text

On page 5, Section 3.2.7, the sentence "In ODYSSEY Outcomes \[19\], neutralizing antibodies developed in 42% and 6% of patients in the alirocumab and placebo group, respectively," should be replaced with "In ODYSSEY Outcomes \[19\], neutralizing antibodies developed in 0.4% and 0.1% of patients in the alirocumab and placebo group, respectively".

The authors would like to apologize for any inconvenience caused to the readers by these changes.

diseases-06-00061-t001_Table 1

###### 

Cardiovascular outcome trials of nonstatin drugs.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                              IMPROVE-IT \[17\]                                                          FOURIER \[18\]                                                             ODYSSEY Outcomes \[19\]
  ------------------------------------- -------------------------------------------------------------------------- -------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  No. of patients                       18,144                                                                     27,564                                                                     18,924

  No. of patients with diabetes         4933 (27%)                                                                 11,031 (40%) \[20\]                                                        5444 (29%)

  Mean age (years)                      64                                                                         63                                                                         58

  Clinical characteristics              ACS within 10 days                                                         ASCVD and LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL on statin                ACS within 12 months; LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL or ApoB ≥80 mg/dL on high-intensity statin

  Intervention                          Simvastatin 40 mg and ezetimibe 10 mg vs. simvastatin 40 mg                Evolocumab 140 mg q 2w or 420 mg q 4w vs. placebo                          Alirocumab 75--150 mg q 2w vs. placebo

  Primary endpoint                      CV death, MI, stroke, hospitalization for UA, coronary revascularization   CV death, MI, stroke, hospitalization for UA, coronary revascularization   CHD death, MI, ischemic stroke, hospitalization for UA

  Median f/u (years)                    6                                                                          2.2                                                                        2.8

  Achieved LDL-C (mg/dL)                53.7 vs. 69.5                                                              30 vs. 92                                                                  53.3 vs. 101.4

  Primary endpoint                      32.7% vs. 34.7%; HR 0.936 (95% CI 0.89--0.99); *p* = 0.016                 9.8% vs. 11.3%; HR 0.85 (95% CI 0.79--0.92); *p* \< 0.001                  9.5% vs. 11.1%; HR 0.85 (95% CI 0.78--0.93); *p* = 0.0003

  3-point MACE (CV death, MI, stroke)   22.2% vs. 20.4%; HR 0.90 (95% CI 0.84--0.96); *p* = 0.003                  5.9% vs. 7.4%; HR 0.80 (95% CI 0.73--0.88); *p*\<0.001                     10.3% vs. 11.9%; HR 0.86 (95% CI 0.79--0.93); *p* = 0.0003 \*

  CV death                              6.8% vs. 6.9%; HR 1.00 (95% CI 0.89--1.13); *p* = 1.00                     1.8% vs. 1.7%; HR 1.05 (95% CI 0.88--1.25); *p* = 0.62                     2.5% vs. 2.9%; HR 0.88 (95% CI 0.74--1.05); *p* = 0.15

  All-cause death                       15.3% vs. 15.4%; HR 0.99 (95% CI 0.91--1.07); *p* = 0.78                   3.2% vs. 3.1%; HR 1.04 (95% CI 0.91--1.19); *p* = 0.54                     3.5% vs. 4.1%; HR 0.85 (95% CI 0.73--0.98); *p* = 0.026

  Adverse events                        Similar safety in both groups                                              Injection-site reactions: 2.1% vs. 1.6%\                                   Injection site reactions: 3.8% vs. 2.1%\
                                                                                                                   Neutralizing antibodies: 0% in both groups                                 Neutralizing antibodies: 42% vs. 6%
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACS = acute coronary syndrome; AMI = acute myocardial infarction; ApoB = apolipoprotein B; ASCVD = atherosclerotic cardiovascular disease; CHD = coronary heart disease; CI = confidence interval; CV = cardiovascular; FOURIER = Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk; HR = hazard ratio; HDL-C = high-density lipoprotein cholesterol; IMPROVE-IT = Improved Reduction of outcomes: Vytorin Efficacy International Trial; LDL-C = low-density lipoprotein cholesterol; MACE = major adverse cardiovascular events; MI = myocardial infarction; UA = unstable angina; \* 3-point MACE for all-cause death, MI, stroke.

diseases-06-00061-t002_Table 2

###### 

Cardiovascular outcome trials of nonstatin drugs.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                              IMPROVE-IT \[17\]                                                          FOURIER \[18\]                                                             ODYSSEY Outcomes \[19\]
  ------------------------------------- -------------------------------------------------------------------------- -------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  No. of patients                       18,144                                                                     27,564                                                                     18,924

  No. of patients with diabetes         4933 (27%)                                                                 11,031 (40%) \[20\]                                                        5444 (29%)

  Mean age (years)                      64                                                                         63                                                                         58

  Clinical characteristics              ACS within 10 days                                                         ASCVD and LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL on statin                ACS within 12 months; LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL or ApoB ≥80 mg/dL on high-intensity statin

  Intervention                          Simvastatin 40 mg and ezetimibe 10 mg vs. simvastatin 40 mg                Evolocumab 140 mg q 2w or 420 mg q 4w vs. placebo                          Alirocumab 75--150 mg q 2w vs. placebo

  Primary endpoint                      CV death, MI, stroke, hospitalization for UA, coronary revascularization   CV death, MI, stroke, hospitalization for UA, coronary revascularization   CHD death, MI, ischemic stroke, hospitalization for UA

  Median f/u (years)                    6                                                                          2.2                                                                        2.8

  Achieved LDL-C (mg/dL)                53.7 vs. 69.5                                                              30 vs. 92                                                                  53.3 vs. 101.4

  Primary endpoint                      32.7% vs. 34.7%; HR 0.936 (95% CI 0.89--0.99); *p* = 0.016                 9.8% vs. 11.3%; HR 0.85 (95% CI 0.79--0.92); *p* \< 0.001                  9.5% vs. 11.1%; HR 0.85 (95% CI 0.78--0.93); *p* = 0.0003

  3-point MACE (CV death, MI, stroke)   22.2% vs. 20.4%; HR 0.90 (95% CI 0.84--0.96); *p* = 0.003                  5.9% vs. 7.4%; HR 0.80 (95% CI 0.73--0.88); *p*\<0.001                     10.3% vs. 11.9%; HR 0.86 (95% CI 0.79--0.93); *p* = 0.0003 \*

  CV death                              6.8% vs. 6.9%; HR 1.00 (95% CI 0.89--1.13); *p* = 1.00                     1.8% vs. 1.7%; HR 1.05 (95% CI 0.88--1.25); *p* = 0.62                     2.5% vs. 2.9%; HR 0.88 (95% CI 0.74--1.05); *p* = 0.15

  All-cause death                       15.3% vs. 15.4%; HR 0.99 (95% CI 0.91--1.07); *p* = 0.78                   3.2% vs. 3.1%; HR 1.04 (95% CI 0.91--1.19); *p* = 0.54                     3.5% vs. 4.1%; HR 0.85 (95% CI 0.73--0.98); *p* = 0.026

  Adverse events                        Similar safety in both groups                                              Injection-site reactions: 2.1% vs. 1.6%\                                   Injection site reactions: 3.8% vs. 2.1%\
                                                                                                                   Neutralizing antibodies: 0% in both groups                                 Neutralizing antibodies: 0.4% vs. 0.1%
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACS = acute coronary syndrome; AMI = acute myocardial infarction; ApoB = apolipoprotein B; ASCVD = atherosclerotic cardiovascular disease; CHD = coronary heart disease; CI = confidence interval; CV = cardiovascular; FOURIER = Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk; HR = hazard ratio; HDL-C = high-density lipoprotein cholesterol; IMPROVE-IT = Improved Reduction of outcomes: Vytorin Efficacy International Trial; LDL-C = low-density lipoprotein cholesterol; MACE = major adverse cardiovascular events; MI = myocardial infarction; UA = unstable angina; \* 3-point MACE for all-cause death, MI, stroke.
